Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder
Deepak Cyril D’Souza, Shariful A. Syed, L. Taylor Flynn, et al.
Neuropsychopharmacology (2022) Vol. 47, Iss. 10, pp. 1854-1862
Open Access | Times Cited: 100

Showing 1-25 of 100 citing articles:

Human brain effects of DMT assessed via EEG-fMRI
Christopher Timmermann, Leor Roseman, Sharad Haridas, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 13
Open Access | Times Cited: 129
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
Jordan Sloshower, Patrick D. Skosnik, Hamideh Safi-Aghdam, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 698-706
Closed Access | Times Cited: 85
Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants
Severin B. Vogt, Laura Ley, Livio Erne, et al.
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 48
Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?
Kenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience (2024)
Open Access | Times Cited: 28
Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis
Yuan Yao, Dan Guo, Tangsheng Lu, et al.
Psychiatry Research (2024) Vol. 335, pp. 115886-115886
Closed Access | Times Cited: 24
Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile
Friederike Holze, Nirmal Singh, Matthias E. Liechti, et al.
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2024) Vol. 9, Iss. 5, pp. 472-489
Open Access | Times Cited: 20
Adverse Events in Studies of Classic Psychedelics
Jared T. Hinkle, Marianna Graziosi, Sandeep M. Nayak, et al.
JAMA Psychiatry (2024)
Closed Access | Times Cited: 19
Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study
Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 18
Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study
Natasha L. Mason, Attila Szabó, Kim P. C. Kuypers, et al.
Brain Behavior and Immunity (2023) Vol. 114, pp. 299-310
Open Access | Times Cited: 38
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Andrea Mastinu, Margrate Anyanwu, Marinella Carone, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1329-1329
Open Access | Times Cited: 36
Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants
Wenwen Duan, Dongmei Cao, Sheng Wang, et al.
Chemical Reviews (2023) Vol. 124, Iss. 1, pp. 124-163
Closed Access | Times Cited: 30
Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants
Tao Chen, Ling Cheng, Jingwen Ma, et al.
Pharmacological Research (2023) Vol. 194, pp. 106837-106837
Open Access | Times Cited: 24
Effects of DMT on mental health outcomes in healthy volunteers
Christopher Timmermann, Richard J. Zeifman, David Erritzøe, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 14
Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial
Jordan Sloshower, Richard J. Zeifman, Jeffrey Guss, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 14
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Bryan Barksdale, Manoj K. Doss, Gregory A. Fonzo, et al.
Neurotherapeutics (2024), pp. e00322-e00322
Open Access | Times Cited: 13
N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer’s disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk
Dan Cheng, Zhuogui Lei, Kin Chu, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 13
Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial
Emmanuelle A. D. Schindler, R. Andrew Sewell, Christopher Gottschalk, et al.
Journal of the Neurological Sciences (2024) Vol. 460, pp. 122993-122993
Closed Access | Times Cited: 12
Treatment-Resistant Depression
Marcus Hughes, Steven R. Levine
Elsevier eBooks (2024)
Closed Access | Times Cited: 10
Psychedelics in Psychiatry: Oh, What A Trip!
Gregory A. Fonzo, Charles B. Nemeroff, Ned H. Kalin
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 1-5
Closed Access | Times Cited: 1
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Johannes G. Ramaekers, Johannes T. Reckweg, Natasha L. Mason
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 33-46
Closed Access | Times Cited: 1
Exploring DMT: Endogenous Role and Therapeutic Potential
J. Schimmelpfennig, Kamila Jankowiak-Siuda
Neuropharmacology (2025), pp. 110314-110314
Open Access | Times Cited: 1
Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis
Katelijne V. van der Heijden, Marije E. Otto, Jan W. Schoones, et al.
Clinical Pharmacokinetics (2025)
Open Access | Times Cited: 1
A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions
Bill Brennan, Alex R. Kelman, Alexander B. Belser
Psychedelic Medicine (2023) Vol. 1, Iss. 4, pp. 218-229
Open Access | Times Cited: 21
Beyond the 5-HT2AReceptor: Classic and Nonclassic Targets in Psychedelic Drug Action
Lindsay P. Cameron, Joseph Benetatos, Vern Lewis, et al.
Journal of Neuroscience (2023) Vol. 43, Iss. 45, pp. 7472-7482
Open Access | Times Cited: 21
Role of Psychedelics in Treatment-Resistant Depression
Shubham Kamal, Manish K. Jha, Rajiv Radhakrishnan
Psychiatric Clinics of North America (2023) Vol. 46, Iss. 2, pp. 291-305
Closed Access | Times Cited: 20
Page 1 - Next Page

Scroll to top